Key Points
- On April 17, insider David Malcom Rodman sold 416 shares of Mineralys Therapeutics (MLYS) at an average price of $31.33 for $13,033.28 under a pre-arranged Rule 10b5-1 plan, leaving him with 69,792 shares (≈$2.19M), a 0.59% decrease in his position.
- This trade is part of repeated recent insider selling by Rodman between February and April, including multiple large blocks (e.g., 14,058- and 6,348-share sales), totaling hundreds of thousands of dollars.
- For context, MLYS shares opened at $28.78 and are down 4.3%; the company has a $2.37B market cap and a consensus analyst rating of "Moderate Buy" with an average price target of $49.14.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $31.33, for a total transaction of $13,033.28. Following the transaction, the insider owned 69,792 shares in the company, valued at approximately $2,186,583.36. This trade represents a 0.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Malcom Rodman also recently made the following trade(s):
- On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total transaction of $175,585.68.
- On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total transaction of $373,099.32.
- On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.38, for a total transaction of $59,414.60.
- On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total transaction of $173,744.76.
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total transaction of $58,269.64.
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.59, for a total transaction of $11,505.03.
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total transaction of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total transaction of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total transaction of $65,585.91.
Mineralys Therapeutics Stock Down 4.3%
NASDAQ MLYS opened at $28.78 on Wednesday. Mineralys Therapeutics, Inc. has a 52 week low of $12.59 and a 52 week high of $47.65. The firm has a market capitalization of $2.37 billion, a P/E ratio of -12.14 and a beta of 0.69. The company has a 50-day moving average price of $27.24 and a 200-day moving average price of $34.07.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. As a group, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -2.28 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on MLYS shares. HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the company a "buy" rating in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Bank of America upped their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a "buy" rating in a research report on Friday, March 13th. Wall Street Zen raised shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $49.14.
Get Our Latest Stock Analysis on MLYS
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd grew its stake in shares of Mineralys Therapeutics by 3,439.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,823 shares of the company's stock valued at $139,000 after acquiring an additional 3,715 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Mineralys Therapeutics during the 4th quarter valued at approximately $553,000. XTX Topco Ltd grew its stake in shares of Mineralys Therapeutics by 291.1% during the 4th quarter. XTX Topco Ltd now owns 73,678 shares of the company's stock valued at $2,674,000 after acquiring an additional 54,838 shares during the period. Ikarian Capital LLC bought a new position in shares of Mineralys Therapeutics during the 4th quarter valued at approximately $7,258,000. Finally, Sphera Funds Management LTD. grew its stake in shares of Mineralys Therapeutics by 104.2% during the 4th quarter. Sphera Funds Management LTD. now owns 449,003 shares of the company's stock valued at $16,294,000 after acquiring an additional 229,093 shares during the period. 84.46% of the stock is currently owned by institutional investors.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
